Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer
- 1 August 2006
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 102 (2) , 140-144
- https://doi.org/10.1016/j.ygyno.2006.05.006
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targetsInternational Journal of Gynecologic Cancer, 2005
- Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumabJournal of Surgical Oncology, 2005
- Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancerGynecologic Oncology, 2005
- Should CA-125 Response Criteria Be Preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for Prognostication During Second-Line Chemotherapy of Ovarian Carcinoma?Journal of Clinical Oncology, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Use of CA-125 to Assess Response to New Agents in Ovarian Cancer TrialsJournal of Clinical Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958